5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer

Massimo Lopez, Carlo Federico Perno, Luigi Di Lauro, Paola Papaldo

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median survival of all 32 patients, 7 months. Responding patients had significantly better survival than the nonresponders (P60.001). Analysis of the results according to pretreatment performance status, resectability of the primary tumor, and histologic differentiation of the malignancy demonstrates that only the first influenced the therapeutic results. The FAB regimen was well tolerated, allowing administration of nearly the whole of the projected drug dosages during the course of the therapy in all but three patients. These results indicate that the FAB combination is an effective chemotherapeutic regimen in metastatic or locally advanced gastric carcinoma. Incorporation of this regimen into the design of combined-modality treatment would result in improved prognosis.

Original languageEnglish
Pages (from-to)194-197
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume12
Issue number3
DOIs
Publication statusPublished - Apr 1984

Fingerprint

Carmustine
Chemotherapy
Combination Drug Therapy
Fluorouracil
Doxorubicin
Stomach Neoplasms
Drug dosage
Stomach
Survival
Tumors
Neoplasms
Adenocarcinoma
Therapeutics
Carcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. / Lopez, Massimo; Federico Perno, Carlo; Di Lauro, Luigi; Papaldo, Paola.

In: Cancer Chemotherapy and Pharmacology, Vol. 12, No. 3, 04.1984, p. 194-197.

Research output: Contribution to journalArticle

@article{fc6e2bf41aa4477ca3ad37e41575a448,
title = "5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer",
abstract = "Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50{\%}. The median duration of response was 10 months, and the median survival of all 32 patients, 7 months. Responding patients had significantly better survival than the nonresponders (P60.001). Analysis of the results according to pretreatment performance status, resectability of the primary tumor, and histologic differentiation of the malignancy demonstrates that only the first influenced the therapeutic results. The FAB regimen was well tolerated, allowing administration of nearly the whole of the projected drug dosages during the course of the therapy in all but three patients. These results indicate that the FAB combination is an effective chemotherapeutic regimen in metastatic or locally advanced gastric carcinoma. Incorporation of this regimen into the design of combined-modality treatment would result in improved prognosis.",
author = "Massimo Lopez and {Federico Perno}, Carlo and {Di Lauro}, Luigi and Paola Papaldo",
year = "1984",
month = "4",
doi = "10.1007/BF00256545",
language = "English",
volume = "12",
pages = "194--197",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - 5-Fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer

AU - Lopez, Massimo

AU - Federico Perno, Carlo

AU - Di Lauro, Luigi

AU - Papaldo, Paola

PY - 1984/4

Y1 - 1984/4

N2 - Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median survival of all 32 patients, 7 months. Responding patients had significantly better survival than the nonresponders (P60.001). Analysis of the results according to pretreatment performance status, resectability of the primary tumor, and histologic differentiation of the malignancy demonstrates that only the first influenced the therapeutic results. The FAB regimen was well tolerated, allowing administration of nearly the whole of the projected drug dosages during the course of the therapy in all but three patients. These results indicate that the FAB combination is an effective chemotherapeutic regimen in metastatic or locally advanced gastric carcinoma. Incorporation of this regimen into the design of combined-modality treatment would result in improved prognosis.

AB - Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB). Two complete and fourteen partial responses were observed, with an overall response rate of 50%. The median duration of response was 10 months, and the median survival of all 32 patients, 7 months. Responding patients had significantly better survival than the nonresponders (P60.001). Analysis of the results according to pretreatment performance status, resectability of the primary tumor, and histologic differentiation of the malignancy demonstrates that only the first influenced the therapeutic results. The FAB regimen was well tolerated, allowing administration of nearly the whole of the projected drug dosages during the course of the therapy in all but three patients. These results indicate that the FAB combination is an effective chemotherapeutic regimen in metastatic or locally advanced gastric carcinoma. Incorporation of this regimen into the design of combined-modality treatment would result in improved prognosis.

UR - http://www.scopus.com/inward/record.url?scp=0021350890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021350890&partnerID=8YFLogxK

U2 - 10.1007/BF00256545

DO - 10.1007/BF00256545

M3 - Article

VL - 12

SP - 194

EP - 197

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -